TY - JOUR
T1 - Radiotherapy dosing for locally advanced non-small cell lung carcinoma
T2 - "MTD" or "ALARA"?
AU - Ohri, Nitin
N1 - Publisher Copyright:
© 2017 Ohri.
PY - 2017/9/21
Y1 - 2017/9/21
N2 - Locally advanced non-small cell lung cancer (LA-NSCLC) is typically treated with thoracic radiotherapy, often in combination with cytotoxic chemotherapy. Despite tremendous advances in the evaluation, treatment techniques, and supportive care measures provided to LA-NSCLC patients, local disease progression and distant metastases frequently develop following definitive therapy. A recent landmark randomized trial demonstrated that radiotherapy dose escalation may reduce survival rates, highlighting our poor understanding of the effects of thoracic radiotherapy for LA-NSCLC. Here, we present rationale for further studies of radiotherapy dose escalation as well as arguments for exploring relatively low radiotherapy doses for LA-NSCLC.
AB - Locally advanced non-small cell lung cancer (LA-NSCLC) is typically treated with thoracic radiotherapy, often in combination with cytotoxic chemotherapy. Despite tremendous advances in the evaluation, treatment techniques, and supportive care measures provided to LA-NSCLC patients, local disease progression and distant metastases frequently develop following definitive therapy. A recent landmark randomized trial demonstrated that radiotherapy dose escalation may reduce survival rates, highlighting our poor understanding of the effects of thoracic radiotherapy for LA-NSCLC. Here, we present rationale for further studies of radiotherapy dose escalation as well as arguments for exploring relatively low radiotherapy doses for LA-NSCLC.
KW - Chemoradiotherapy
KW - Dose-response relationship
KW - Locally advanced NSCLC
KW - Lung cancer
KW - Radiation
KW - Radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=85029787577&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85029787577&partnerID=8YFLogxK
U2 - 10.3389/fonc.2017.00205
DO - 10.3389/fonc.2017.00205
M3 - Review article
AN - SCOPUS:85029787577
SN - 2234-943X
VL - 7
JO - Frontiers in Oncology
JF - Frontiers in Oncology
IS - SEP
M1 - 205
ER -